
Sign up to save your podcasts
Or


Send us a text
In this episode of WTR Small-Cap Spotlight, Dr. David Sans, healthcare investment banker, former Novartis oncology researcher, and long-time biotech strategist, joins host Tim Gerdeman, Vice Chair, Co-Founder, and Chief Marketing Officer of Water Tower Research, for an in-depth discussion on the state of the biotech industry. Together, they explore why optimism is returning to the sector, which technologies and therapeutic categories are leading the rebound, and how investment and IPO trends are shaping the next phase of biotech growth. Discover the bullish underpinnings of The Wall Street Journal article last week titled “Why Biotech’s Rally Can Last This Time”.
By Water Tower Research5
88 ratings
Send us a text
In this episode of WTR Small-Cap Spotlight, Dr. David Sans, healthcare investment banker, former Novartis oncology researcher, and long-time biotech strategist, joins host Tim Gerdeman, Vice Chair, Co-Founder, and Chief Marketing Officer of Water Tower Research, for an in-depth discussion on the state of the biotech industry. Together, they explore why optimism is returning to the sector, which technologies and therapeutic categories are leading the rebound, and how investment and IPO trends are shaping the next phase of biotech growth. Discover the bullish underpinnings of The Wall Street Journal article last week titled “Why Biotech’s Rally Can Last This Time”.

228,886 Listeners

3,213 Listeners

3,376 Listeners

1,283 Listeners

9,545 Listeners

1,202 Listeners

9,438 Listeners

112,401 Listeners

2,027 Listeners

1,043 Listeners

196 Listeners

10,015 Listeners

248 Listeners

1,429 Listeners

20 Listeners